Nuveen
VRDN icon

Nuveen’s Viridian Therapeutics VRDN Stock Holding History

Nuveen’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.66M Sell
199,230
-405,684
-67% -$6.54M ﹤0.01% 2277
2026
Q1 		$11.8M Sell
604,914
-137,423
-19% -$4.08M ﹤0.01% 1455
2025
Q4 		$23.1M Buy
742,337
+580,469
+359% +$15.9M 0.01% 1065
2025
Q3 		$3.49M Sell
161,868
-61,367
-27% -$1.11M ﹤0.01% 2079
2025
Q2 		$3.12M Sell
223,235
-25,393
-10% -$345K ﹤0.01% 2102
2025
Q1 		$3.35M Sell
248,628
-432,384
-63% -$7.36M ﹤0.01% 2121
2024
Q4 		$13.1M Buy
681,012
+452,627
+198% +$9.84M ﹤0.01% 1453
2024
Q3 		$5.2M Sell
228,385
-270,018
-54% -$4.41M ﹤0.01% 1969
2024
Q2 		$6.48M Sell
498,403
-834,051
-63% -$11.5M ﹤0.01% 1817
2024
Q1 		$23.3M Buy
1,332,454
+1,098,574
+470% +$21.3M 0.01% 1083
2023
Q4 		$5.09M Buy
233,880
+30,439
+15% +$481K ﹤0.01% 1969
2023
Q3 		$3.12M Sell
203,441
-222,754
-52% -$4.25M ﹤0.01% 2104
2023
Q2 		$10.1M Sell
426,195
-151,432
-26% -$3.88M ﹤0.01% 1502
2023
Q1 		$14.7M Buy
577,627
+256,161
+80% +$8.21M 0.01% 1238
2022
Q4 		$10.9M Buy
321,466
+218,717
+213% +$5.04M ﹤0.01% 1431
2022
Q3 		$2.05M Buy
102,749
+43,834
+74% +$788K ﹤0.01% 2393
2022
Q2 		$681K Buy
+58,915
New +$792K ﹤0.01% 2939

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nuveen's VRDN Position: Q2 2026 in Review

Nuveen reduced its Viridian Therapeutics (VRDN) stake by 67% in Q2 2026, selling an estimated $6.54M and leaving 199,230 shares worth $3.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

Nuveen first reported a position in VRDN in Q2 2022 and has held it in 17 quarters since. The position peaked at $23.3M in Q1 2024. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Nuveen held 199,230 shares of Viridian Therapeutics worth $3.66M as of Q2 2026.
  • Nuveen sold 405,684 Viridian Therapeutics shares in Q2 2026, an estimated $6.54M.
  • Viridian Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2277 holding.
  • Nuveen first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Nuveen's Viridian Therapeutics position peaked at $23.3M in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.